Active trials
11
Subjects enrolled
2,184
+38 this week
Sites
42
Approved protocols
9
Trial registry
| ID | Study | Sites | Enrollment | Status |
|---|---|---|---|---|
| CT-2231 | Non-invasive Glucose Validation Phase II | 14 | 482/600 | Enrolling |
| CT-2104 | AF Detection vs 12-lead Holter | 6 | 220/220 | Analysis |
| CT-1998 | SpO2 Accuracy vs Co-Oximeter | 3 | 90/100 | Active |
| CT-2245 | Cortisol Proxy Pilot | 2 | 22/60 | Enrolling |
Clarke Error Grid — CT-2231 glucose validation
n = 12,480 pairedA (clinically accurate)
84.2%
B (benign)
13.1%
C (correction)
1.9%
D (error)
0.7%
E (severe)
0.1%
Statistical metrics
MARD8.2%
MAE11.4 mg/dL
RMSE14.8 mg/dL
Correlation r0.94
R²0.88
Versus YSI 2300 hexokinase reference, n=12,480 paired samples across 14 sites.
Comparator devices
- CGMAbbott Libre 3
- CGMMedtronic Guardian 4
- CGMDexcom G7
- SMBGAccuChek Guide
- SMBGContour Next One
- LabYSI 2300 Stat Plus
- LabHexokinase Method
Regulatory documentation
- ApprovedEthics Committee — CT-2231Mar 12, 2026
- ApprovedCDSCO Application Phase IIApr 02, 2026
- ApprovedICMR RegistrationApr 18, 2026
- PendingISO 13485 QMS auditJul 22, 2026
Site enrollment velocity
Subjects enrolled / monthTarget line: 60